Navigation Links
Baxa Corporation Introduces ExactaMix™ 1200 Automated Compounder for Sterile, Multi-Ingredient Solutions

ENGLEWOOD, Colo., Nov. 9, 2010 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, today introduced the ExactaMix 1200 Automated Compounding Device (ACD) for small- to mid-sized hospital pharmacies in need of an automated approach to compounding large-volume parenteral doses.  The entry-level 12-port compounder extends the market-proven Baxa ExactaMix Product Line and brings delivery precision and safe handling to pharmacies that want the compounding safety and efficiency that automation offers, but don't require the full range of the ExactaMix 2400 Compounder's capabilities.  The new ExactaMix 1200 will be exhibited next month at the 2010 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting (MCM) & Exhibition.

The ExactaMix products automatically compound sterile doses, minimizing the risk of measurement errors, wrong drug selection, touch contamination and patient infection in the preparation of solutions for TPN, cardioplegia, dialysis and epidural delivery.  Capable of volumes as low as 0.2 mL, the new ExactaMix 1200 safely and accurately delivers both micro and macro ingredients. The ExactaMix 1200 and ExactaMix 2400 are the only ACDs with both volumetric delivery and gravimetric check, enabling pharmacists to ensure accuracy with both volume and fill data.

State-of-the-art Baxa compounding technology delivers final bag accuracies within +/- 4% with barcode ingredient verification, and pumps a typical three-liter nutrition bag in approximately 3.5 minutes -- nearly two times faster than industry average.  Its features improve compounding efficiency, enabling pharmacy professionals to focus on patient care with the confidence that safety, regulatory compliance and preparation accuracy goals are met.

"The ExactaMix 1200 dispels the myth that only large healthcare facilities and hospitals can take advantage of the safety and efficiency of proven, cutting-edge automated compounding technology," said Laura Zoerner, Senior Product Manager at Baxa Corporation.  "With the addition of the 12-port compounder, we now offer a wider range of solutions with globally recognized ExactaMix Technology. Now virtually any hospital can afford automated compounding for therapies such as TPN, cardioplegia and dialysis and epidural solutions to achieve both accuracy and speed -- while maintaining USP <797> compliance and delivering exactly right doses."

In its 45th year, the MCM takes place December 5 – 9, 2010 at the Anaheim Convention Center in Anaheim, California.  In addition to ExactaMix 1200, Baxa will showcase its extensive line of solutions that efficiently and safely deliver more than 450,000 doses each day, including its DoseEdge™ Pharmacy Workflow Management System.  Over 5 million doses have been processed by DoseEdge in US hospitals to date.  DoseEdge has prevented more than 100,000 preparation errors through barcode verification of every ingredient drug and best-practice compounding process management.  To view technical videos or download educational materials on FormularyPlus enhancements for DoseEdge, visit

Baxa Corporation reliably and consistently enables pharmacists at more than 3,000 hospitals worldwide to safely prepare and administer intravenous therapies.  To learn more about the ExactaMix 1200, visit  For additional information, to request a product brochure or download a free, educational white paper, visit, call 800-567-2292 or email

About Baxa CorporationBaxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery.  Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications.  Key products include the Abacus® Order Entry and Calculation Software, the DoseEdge™ Pharmacy Workflow Manager, ExactaMed® Oral Syringes, ExactaMix™ Automated Compounding Devices, InFuse™ and MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, NeoThrive® Enteral Syringes, the PadLock®  Set Saver and the RapidFill™ Automated Syringe Filler; used worldwide in hospitals and healthcare facilities.  Its subsidiary FHT, Inc. produces the IntelliFill® i.v. automation.  Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide.  Further information is available at Robinson, Vice President, MarketingBaxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157Email:  marian.robinson@baxa.comPerrin McCormick or Brandie GerrishHart-Boillot: 781-893-0053Email:

SOURCE Baxa Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
(Date:11/27/2015)... 2015 Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... Une nouvelle approche consistant à combiner l,immunothérapie au ...    Clinical Cancer Research . ...
(Date:11/27/2015)... DUBLIN , Nov. 26, 2015 /PRNewswire/ ... announced the addition of the "2016 ... by Test, Country Volume and Sales Segment ... Emerging Opportunities" report to their offering. ... the addition of the "2016 Global ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog ... effect tool designed specially for Final Cut Pro X. FCPX users ... the easy-to-use modification controls. Destoying and creating chaotic distortion is now quick and ...
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an ... due to personal experience with a bad back," he said. , This easy-to-use, versatile ... as increases support. It also makes it easier to eat, do other activities and ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of the ... 2016, at Caesars Palace in Las Vegas with a pre-conference session on a ...
Breaking Medicine News(10 mins):